As the Australian market remains relatively flat, with the ASX hovering close to 8,542 points and sectors like IT outperforming while Materials face pressure, investors are closely watching potential tax reforms that could impact future economic conditions. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Titomic (ASX:TTT) | 11.2% | 77.2% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| Image Resources (ASX:IMA) | 20.6% | 79.9% |
| Fenix Resources (ASX:FEX) | 21.1% | 53.4% |
| Echo IQ (ASX:EIQ) | 18% | 65.9% |
| Cyclopharm (ASX:CYC) | 11.3% | 97.8% |
| Brightstar Resources (ASX:BTR) | 11.6% | 106.7% |
| Alfabs Australia (ASX:AAL) | 10.8% | 41.3% |
| Adveritas (ASX:AV1) | 21% | 88.8% |
| Acrux (ASX:ACR) | 15.5% | 106.9% |
Let's review some notable picks from our screened stocks.
Aurelia Metals (ASX:AMI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Aurelia Metals Limited is involved in the exploration and production of mineral properties in Australia, with a market cap of A$516.23 million.
Operations: The company's revenue is derived from its operations at the Hera Mine (A$5.98 million), Peak Mine (A$245.13 million), and Dargues Mine (A$73.90 million).
Insider Ownership: 23.9%
Revenue Growth Forecast: 14.6% p.a.
Aurelia Metals is poised for significant growth, with earnings expected to rise 45.29% annually, outpacing the Australian market's 11.6%. Revenue growth is projected at 14.6% per year, surpassing the market average of 5.6%. The stock trades at a substantial discount to its estimated fair value, suggesting potential upside. Recent events include an Analyst/Investor Day focusing on strategic growth opportunities and a change in registered office location to Brisbane, enhancing operational efficiency.
- Click to explore a detailed breakdown of our findings in Aurelia Metals' earnings growth report.
- Our valuation report unveils the possibility Aurelia Metals' shares may be trading at a premium.
PWR Holdings (ASX:PWH)
Simply Wall St Growth Rating: ★★★★★☆
Overview: PWR Holdings Limited specializes in the design, prototyping, production, testing, validation, and sale of cooling products and solutions across various international markets with a market cap of A$661.71 million.
Operations: PWR Holdings Limited generates revenue from two main segments: PWR C&R, contributing A$46.48 million, and PWR Performance Products, contributing A$109.04 million.
Insider Ownership: 13.3%
Revenue Growth Forecast: 13.4% p.a.
PWR Holdings is positioned for robust growth, with earnings anticipated to increase by 24.56% annually, exceeding the Australian market's average of 11.6%. Analysts agree on a potential stock price rise of 25.6%, while it currently trades at a discount to its fair value estimate. Insider confidence is evident with substantial share purchases and no significant sales over the past three months, reinforcing positive sentiment around its future performance.
- Take a closer look at PWR Holdings' potential here in our earnings growth report.
- The analysis detailed in our PWR Holdings valuation report hints at an deflated share price compared to its estimated value.
Telix Pharmaceuticals (ASX:TLX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases across Australia, Belgium, Japan, Switzerland, and the United States, with a market cap of A$8.71 billion.
Operations: The company's revenue is primarily derived from three segments: Therapeutics (A$9.35 million), Precision Medicine (A$771.11 million), and Manufacturing Solutions (A$2.75 million).
Insider Ownership: 14.9%
Revenue Growth Forecast: 19.8% p.a.
Telix Pharmaceuticals is experiencing significant growth, with earnings expected to increase by 32.8% annually, outpacing the Australian market average. The company trades at a considerable discount to its fair value estimate and shows no substantial insider selling recently, indicating confidence in its prospects. Recent approvals of Telix's prostate cancer imaging agents across Europe and the U.S., including Illuccix® and Gozellix®, enhance its market presence and support future revenue expansion.
- Click here and access our complete growth analysis report to understand the dynamics of Telix Pharmaceuticals.
- Insights from our recent valuation report point to the potential undervaluation of Telix Pharmaceuticals shares in the market.
Seize The Opportunity
- Investigate our full lineup of 94 Fast Growing ASX Companies With High Insider Ownership right here.
- Contemplating Other Strategies? Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Telix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com